Maurice Perrinjaquet

Maurice Perrinjaquet is a life sciences strategy partner at EY. He advises pharmaceutical, biotech and contract development and manufacturing (CDMO) companies on R&D strategy, clinical development, business development and licensing, market access and commercialisation. His work covers the whole product lifecycle, from deciding which early-stage assets to prioritise to finding new patient groups for therapies already on the market.

He works across all major therapeutic areas and modalities, including cell and gene therapies, radiopharmaceuticals, cancer vaccines, biologics and small molecules. Part of his work concerns China: he helps companies judge how ready its healthcare system is for new treatments, what market adoption depends on, and which cross-border licensing and investment deals make sense.

Perrinjaquet holds a PhD. Before moving into strategy consulting he managed paediatric oncology clinical trials at Memorial Sloan Kettering Cancer Center in New York.